• 1
    Bae JM, Won YJ, Jung KW, Park JG. Annual report of the Korea central cancer registry program 2000: based on registered data from 131 hospitals. Cancer Research and Treatment 2002; 34: 7783.
  • 2
    Kim HS, Lee YC, Lee HW, Yu HM, Lee CK, Kim JH, Lee CJ, Kim BS, Moon BS, Park HJ, Kim DY, Lee CS, et al. Seroepidemiologic study of Helicobacter pylori infection in Korea. Kor J Gastroenterol 1999; 33: 17082.
  • 3
    Kim JH, Kim HY, Kim NY, Kim JG, Kim SW, Kim JJ, Roe IH, Sin JG, Ahn HS, Yoon BC, Lee SW, Lee YC, et al. Seroprevalence of Helicobacter pylori infection in asymptomatic people in Korea. Kor J Med 2000; 59: 38897.
  • 4
    Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998; 114: 116979.
  • 5
    Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 1999; 94: 23739.
    Direct Link:
  • 6
    Atherton JC, Peek RM Jr, Tham KT, Cover TL, Blaser MJ. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterolgy 1997; 112: 929.
  • 7
    van Doorn LJ, Figueiredo C, Sanna R, Pena S, Midolo P, Ng EK, Atherton JC, Blaser MJ, Quint WG. Expanding allelic diversity of Helicobacter pylori vacA. J Clin Microbiol 1998; 36: 2597603.
  • 8
    Miehlke S, Kibler K, Kim JG, Figura N, Small SM, Graham DY, Go MF. Allelic variation in the cagA gene of Helicobacter pylori obtained from Korea compared to the United States. Am J Gastroenterol 1996; 91: 13225.
  • 9
    Lee JW, Jeong S, Kim IH, Kwon KS, Choi W, Lee DH, Cho HG, Kim PS, Kim HG, Shin YW, Kim YS, Choe YH, et al. Relationship between gene subtype of Helicobacter pylori virulence factor and upper gastrointestinal diseases. Korean J Gastroenterol 2001; 38: 8997.
  • 10
    Park SK, Kim GH, Jeong EJ, Bae YM, Heo J, Chu HJ, Kang DH, Song GA, Cho M, Yang WS. Clinical relevance between the cagA, vacA, and iceA status of Helicobacter pylori and benign gastroduodenal diseases. Korean J Gastroenterol 2002; 40: 2331.
  • 11
    Huntsman DG, Carneiro F, Lewis FR, MacLeod PM, Hayashi A, Monaghan KG, Maung R, Seruca R, Jackson CE, Caldas C. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001; 344: 19049.
  • 12
    Azuma T, Ito S, Sato F, Yamazaki Y, Miyaji H, Ito Y, Suto H, Kuriyama M, Kato T, Kohli Y. The role of the HLA-DQA1 gene in resistance to atrophic gastritis and gastric adenocarcinoma induced by Helicobacter pylori infection. Cancer 1998; 82: 10138.
  • 13
    Jang WH, Yang YI, Yea SS, Lee YJ, Chun JH, Kim HI, Kim MS, Paik KH. The −238 tumor necrosis factor-α promoter polymorphism is associated with decreased susceptibility to cancer. Cancer Lett 2001; 166: 416.
  • 14
    Nishimoto IN, Hanakoa T, Sugimura H, Nagura K, Ihara M, Li X-J, Arai T, Hamada GS, Kowalski LP, Tsugane S. Cytochrome P450 2E1 polymorphism in gastric cancer in Brazil: case-control studies of Japanese Brazilians and non-Japanese Brazilians. Cancer Epidemiol Biomark Prev 2000; 9: 67580.
  • 15
    Saadat I, Saadat M. Glutathione S-transferase M1 and T1 null genotypes and the risk of gastric and colorectal cancers. Cancer Lett 2001; 169: 216.
  • 16
    Katoh T, Boissy R, Nagata N, Kitagawa K, Kuroda Y, Itoh H, Kawamoto T, Bell DA. Inherited polymorphism in the N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and susceptibility to gastric and colorectal adenocarcinoma. Int J Cancer 2000; 85: 469.
  • 17
    Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095147.
  • 18
    Wallace JL, Cucala M, Mugridge K, Parente L. Secretagogue-specific effects of interleukin-1 on gastric acid secretion. Am J Physiol 1991; 261: G55964.
  • 19
    Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16: 2755.
  • 20
    El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398402.
  • 21
    Machado JC, Pharoah P, Sousa S, Carvalho R, Oliveira C, Figueiredo C, Amorim A, Seruca R, Caldas C, Carneiro F, Sobrinho-Simoes M. Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 2001; 121: 8239.
  • 22
    Kato S, Onda M, Yamada S, Matsuda N, Tokunaga A, Matsukura N. Association of the interleukin-1β genetic polymorphism and gastric cancer risk in Japanese. J Gastroenterol 2001; 36: 6969.
  • 23
    Wu MS, Wu CY, Chen CJ, Lin MT, Shun CT, Lin JT. Interleukin-10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese. Int J Cancer 2003; 104: 61723.
  • 24
    Hamajima N, Matsuo K, Saito T, Tajima K, Okuma K, Yamao K, Tominaga S. Interleukin 1 polymorphisms, lifestyle factors, and Helicobacter pylori infection. Jpn J Cancer Res 2001; 92: 3839.
  • 25
    Hwang IR, Kodama T, Kikuchi S, Sakai K, Peterson LE, Graham DY, Yamaoka Y. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1β production in Helicobacter pylori infection. Gastroenterology 2002; 123: 1793803.
  • 26
    Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, Duff GW. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993; 91: 4034.
  • 27
    Furuta T, El-Omar EM, Xiao F, Shirai N, Takashima M, Sugimura H, Sugimurra H. Interleukin 1β polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology 2002; 123: 92105.
  • 28
    Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma—an attempt at a histoclinical classification. Acta Pathol Microbiol Scand 1965; 64: 3149.
  • 29
    Fleming ID, Cooper JS, Henson DE. American Joint Committee on Cancer: manual for staging of cancer, 5th ed. Philadelphia: J.B. Lippincott, 1997.
  • 30
    Sobin LH, Wittekind CH. International Union Against Cancer: TNM classification of malignant tumors. 5th edition. New York: John Wiley and Sons, 1997.
  • 31
    Misumi A, Murakama A, Harada K, Baba K, Akagi M. Definition of carcinoma of the gastric cardia. Langenbecks Arch Chir 1989; 374: 2216.
  • 32
    DiGiovine FS, Takhsh E, Blakemore AI, Duff GW. Single base polymorphism at −511 in the human interleukin-1B gene. Hum Mol Genet 1992; 1: 450.
  • 33
    Stokkers PC, van Aken BE, Basiski N, Reitsma PH, Tytgat GN, van Deventer SJ. Five genetic markers in the interleukin 1 family in relation to inflammatory bowel disease. Gut 1998; 43: 339.
  • 34
    Matsukura N, Yamada S, Kato S, Tomtitchong P, Tajiri T, Miki M, Matsuhisa T, Yamada N. Genetic difference in interleukin-1 beta polymorphisms among four Asian populations: an analysis of the Asian paradox between H. pylori infection and gastric cancer incidence. J Exp Clin Cancer Res 2003; 22: 4755.
  • 35
    Zeng ZR, Hu PJ, Hu S, Pang RP, Chen MH, Ng M, Sung JJY. Association of interleukin 1B gene polymorphisms and gastric cancers in high and low prevalence regions in China. Gut 2003; 52: 16849.
  • 36
    Lee JS, Kim GH, Heo J, Park DY, Jun ES, Kang DH, Song GA, Cho M, Yang US. Helicobacter pylori cagA gene and host interleukin-1 beta and interleukin-1 receptor antagonist gene polymorphisms in gastric carcinoma. Korean J Gastroenterol 2003; 41: 43846.
  • 37
    Lee SG, Kim B, Choi W, Lee I, Choi J, Song K. Lack of association between pro-inflammatory genotypes of the interleukin-1 (IL-1B-31 C/+ and IL-1RN *2/*2) and gastric cancer/duodenal ulcer in Korean population. Cytokine 2003; 21: 16771.
  • 38
    Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992; 22: 396402.
  • 39
    Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol 1998; 47: 1958.
  • 40
    Wilkinson RJ, Patel P, Llewelyn M, Hirsch CS, Pasvol G, Snounou G, Davidson RN, Toossi Z. Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1beta on tuberculosis. J Exp Med 1999; 189: 186374.
  • 41
    Takagi A, Deguchi R, Kobayashi K, Miwa T. Cytokine expressions and H. pylori-associated gastric mucosal lesion. Keio J Med 2002; 51 (Suppl 2): 512.
  • 42
    Shu KH, Lee SH, Cheng CH, Wu MJ, Lian JD. Impact of interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphism on IgA nephropathy. Kidney Int 2000; 58: 7839.